Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-(4-methylpiperazin-1-yl)-N-[5-(2-thienylacetyl)-1,5-dihydropyrrolo[3,4-c]pyrazol-3-yl]benzamide
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule with the molecular formula C23H24N6O2S and a molecular weight of approximately 448.54 g/mol. It belongs to the class of phenylpiperazines and features a pyrrolopyrazole core linked to both a thienylacetyl group and a methylpiperazine-substituted benzamide moiety. The compound is listed in chemical databases as an experimental or screening molecule but has no known clinical use or approved therapeutic indication as of June 2025. Its mechanism of action and biological targets are not described in public sources; it appears primarily in research contexts for chemical biology or screening purposes rather than as an active pharmaceutical ingredient[6][8][10].
- Other names
- 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE4-(4-methylpiperazin-1-yl)-n-{5-[2-(thiophen-2-yl)acetyl]-1h,5h-pyrrolo[3,4-c]pyrazol-3-yl}benzamide4-(4-methylpiperazin-1-yL)-N-(5-(2-thienylacetyl)-1,5-dihydropyrrolo(3,4-C)pyrazol–3-Yl)benzamide
Beyond the preview
Go deeper on 4-(4-methylpiperazin-1-yl)-N-[5-(2-thienylacetyl)-1,5-dihydropyrrolo[3,4-c]pyrazol-3-yl]benzamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-(4-methylpiperazin-1-yl)-N-[5-(2-thienylacetyl)-1,5-dihydropyrrolo[3,4-c]pyrazol-3-yl]benzamide.